JP2007528389A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007528389A5 JP2007528389A5 JP2007502437A JP2007502437A JP2007528389A5 JP 2007528389 A5 JP2007528389 A5 JP 2007528389A5 JP 2007502437 A JP2007502437 A JP 2007502437A JP 2007502437 A JP2007502437 A JP 2007502437A JP 2007528389 A5 JP2007528389 A5 JP 2007528389A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable carrier
- surface area
- specific surface
- acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 20
- 230000003637 steroidlike Effects 0.000 claims description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 9
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 claims description 3
- 229960004766 estradiol valerate Drugs 0.000 claims description 3
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims 6
- 229960004845 drospirenone Drugs 0.000 claims 6
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims 6
- OHZWNMVYJJTNKU-VAFIVCJBSA-N prorenoate Chemical compound C12=CC(=O)CC[C@]2(C)[C@H]2CC[C@](C)([C@](CC3)(O)CCC(O)=O)[C@@H]3[C@@H]2[C@@H]2[C@H]1C2 OHZWNMVYJJTNKU-VAFIVCJBSA-N 0.000 claims 6
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 229960004400 levonorgestrel Drugs 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- 229950003620 asoprisnil Drugs 0.000 claims 3
- GJMNAFGEUJBOCE-MEQIQULJSA-N asoprisnil Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(COC)OC)=CC=C(\C=N\O)C=C1 GJMNAFGEUJBOCE-MEQIQULJSA-N 0.000 claims 3
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 2
- DNHCHRGCTVRAFT-JEHIOXJOSA-N 3-[(7r,8r,9s,10r,13s,14s,17r)-17-hydroxy-10,13-dimethyl-3-oxo-7-propyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]propanoic acid Chemical compound C1C[C@]2(C)[C@@](CCC(O)=O)(O)CC[C@H]2[C@@H]2[C@H](CCC)CC3=CC(=O)CC[C@]3(C)[C@H]21 DNHCHRGCTVRAFT-JEHIOXJOSA-N 0.000 claims 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 claims 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims 2
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 claims 2
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims 2
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 claims 2
- ISSQQUKLQJHHOR-OSNGSNEUSA-N [2-[(6s,8s,9r,10s,11s,13s,14s,16r,17r)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]2(C)C[C@@H]1O ISSQQUKLQJHHOR-OSNGSNEUSA-N 0.000 claims 2
- 229940022663 acetate Drugs 0.000 claims 2
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 2
- 229960002537 betamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 2
- 229960004311 betamethasone valerate Drugs 0.000 claims 2
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- 229960005084 calcitriol Drugs 0.000 claims 2
- 235000020964 calcitriol Nutrition 0.000 claims 2
- 239000011612 calcitriol Substances 0.000 claims 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims 2
- 229940086673 canrenoate Drugs 0.000 claims 2
- PBKZPPIHUVSDNM-WNHSNXHDSA-M canrenoate Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)CCC([O-])=O)[C@@H]4[C@@H]3C=CC2=C1 PBKZPPIHUVSDNM-WNHSNXHDSA-M 0.000 claims 2
- UJVLDDZCTMKXJK-WNHSNXHDSA-N canrenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3C=C2)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 UJVLDDZCTMKXJK-WNHSNXHDSA-N 0.000 claims 2
- 229960005057 canrenone Drugs 0.000 claims 2
- 229960004703 clobetasol propionate Drugs 0.000 claims 2
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims 2
- 229960005465 clobetasone butyrate Drugs 0.000 claims 2
- 229940035811 conjugated estrogen Drugs 0.000 claims 2
- 229960003290 cortisone acetate Drugs 0.000 claims 2
- 229960003843 cyproterone Drugs 0.000 claims 2
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 claims 2
- 229960004976 desogestrel Drugs 0.000 claims 2
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims 2
- 229960001208 eplerenone Drugs 0.000 claims 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims 2
- 229960002061 ergocalciferol Drugs 0.000 claims 2
- 229960005309 estradiol Drugs 0.000 claims 2
- 229930182833 estradiol Natural products 0.000 claims 2
- 229960002568 ethinylestradiol Drugs 0.000 claims 2
- 229960002941 etonogestrel Drugs 0.000 claims 2
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims 2
- HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 claims 2
- 229960000606 medrogestone Drugs 0.000 claims 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims 2
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims 2
- CPHJTSJQUQZOLJ-ISIDMKFXSA-N mespirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@@H]3[C@]1(C)CC[C@@H]1[C@@]4(C)C=CC(=O)C=C4C[C@H]([C@@H]31)SC(=O)C)CC(=O)O2 CPHJTSJQUQZOLJ-ISIDMKFXSA-N 0.000 claims 2
- 229950008481 mespirenone Drugs 0.000 claims 2
- 229940053934 norethindrone Drugs 0.000 claims 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims 2
- 229960001858 norethynodrel Drugs 0.000 claims 2
- 229960000417 norgestimate Drugs 0.000 claims 2
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 229960005205 prednisolone Drugs 0.000 claims 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229960003387 progesterone Drugs 0.000 claims 2
- 239000000186 progesterone Substances 0.000 claims 2
- RRHHMFQGHCFGMH-LAPLKBAYSA-N prorenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3[C@H]3C[C@H]32)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 RRHHMFQGHCFGMH-LAPLKBAYSA-N 0.000 claims 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 2
- 229960002256 spironolactone Drugs 0.000 claims 2
- 229950004131 spirorenone Drugs 0.000 claims 2
- XKCGICBTWRNUCL-KIEAKMPYSA-N spiroxasone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCCO1 XKCGICBTWRNUCL-KIEAKMPYSA-N 0.000 claims 2
- 229950002727 spiroxasone Drugs 0.000 claims 2
- 229960003604 testosterone Drugs 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 2
- 239000008158 vegetable oil Substances 0.000 claims 2
- 235000001892 vitamin D2 Nutrition 0.000 claims 2
- 239000011653 vitamin D2 Substances 0.000 claims 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- 229960003657 dexamethasone acetate Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- NZUIUYWHFPQZBH-HXCATZOESA-N spirorenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(C=CC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 NZUIUYWHFPQZBH-HXCATZOESA-N 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55133004P | 2004-03-10 | 2004-03-10 | |
| EP04075714 | 2004-03-10 | ||
| US60/551,330 | 2004-03-10 | ||
| EP04075714.8 | 2004-03-10 | ||
| PCT/IB2005/000748 WO2005087199A2 (en) | 2004-03-10 | 2005-03-10 | Stabilised supersaturated solid solutions of steroidal drugs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007528389A JP2007528389A (ja) | 2007-10-11 |
| JP2007528389A5 true JP2007528389A5 (enExample) | 2008-05-01 |
| JP5006185B2 JP5006185B2 (ja) | 2012-08-22 |
Family
ID=34928105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007502437A Expired - Fee Related JP5006185B2 (ja) | 2004-03-10 | 2005-03-10 | 安定化した過飽和固体親油性薬物 |
Country Status (32)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10172810B2 (en) | 2003-02-24 | 2019-01-08 | Pharmaceutical Productions, Inc. | Transmucosal ketamine delivery composition |
| US20060292223A1 (en) * | 2005-06-16 | 2006-12-28 | Warner Chilcott Company Inc, | Gel compositions for topical administration |
| CN101237851B (zh) * | 2005-06-16 | 2013-09-18 | 沃纳奇尔科特有限责任公司 | 用于阴道给药的雌激素组合物 |
| JP2009536165A (ja) * | 2006-05-10 | 2009-10-08 | エボニック デグサ ゲーエムベーハー | 医薬組成物におけるロール圧縮された熱分解的に製造された二酸化ケイ素の使用 |
| EP2118082B1 (en) | 2007-02-23 | 2014-10-01 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| RU2485949C2 (ru) * | 2007-04-11 | 2013-06-27 | Фармасьютикал Продакшнс Инк | Таблетка мелатонина и способы изготовления и применения |
| WO2009101021A2 (en) * | 2008-02-13 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Estradiol-containing drug delivery system |
| WO2009113522A1 (ja) | 2008-03-11 | 2009-09-17 | あすか製薬株式会社 | 固体分散体とその医薬組成物、並びにそれらの製造方法 |
| AP3089A (en) | 2008-05-02 | 2015-01-31 | Gilead Sciences Inc | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| WO2009138224A1 (en) * | 2008-05-14 | 2009-11-19 | Helm Ag | Pharmaceutical composition comprising drospirenone |
| JP2012505253A (ja) * | 2008-10-10 | 2012-03-01 | テバ ウィメンズ ヘルス インコーポレイテッド | 低用量酢酸シプロテロンを用いる、去勢された前立腺癌患者における血管運動症状の治療方法 |
| EP2398461A1 (en) * | 2009-02-18 | 2011-12-28 | Bayer Pharma Aktiengesellschaft | Formulation comprising drospirenone for subcutaneous or intramuscular administration |
| CN102413813B (zh) * | 2009-03-24 | 2014-11-12 | Adds制药有限责任公司 | 用于口服递送的稳定化的溶解性增强的制剂 |
| FR2947178B1 (fr) * | 2009-06-29 | 2012-07-06 | Effik | Composition pharmaceutique a base de progesterone micronisee et ses utilisations |
| AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
| US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| US11351122B1 (en) | 2010-07-28 | 2022-06-07 | Laboratorios Leon Farma Sa | Synthetic progestogens and pharmaceutical compositions comprising the same |
| US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| WO2012120365A1 (en) | 2011-03-07 | 2012-09-13 | Aurobindo Pharma Limited | Stable pharmaceutical composition comprising ethinyl estradiol |
| US20140178479A1 (en) * | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
| CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| PL2919903T3 (pl) | 2012-11-14 | 2020-12-14 | W.R. Grace & Co. - Conn. | Kompozycje zawierające materiał biologicznie aktywny i nieuporządkowany tlenek nieorganiczny |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US20140303128A1 (en) * | 2013-03-14 | 2014-10-09 | Pharmaceutical Productions Inc. | Transmucosal hormone delivery system |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| AU2015292915B2 (en) | 2014-07-21 | 2020-10-15 | Pharmaceutical Productions, Inc. | Solid dosage form composition for buccal or sublingual administration of cannabinoids |
| AU2015296609A1 (en) | 2014-07-29 | 2016-12-22 | Therapeuticsmd, Inc. | Transdermal cream |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| CN106109420B (zh) * | 2016-08-11 | 2018-07-06 | 吴启旸 | 依普利酮固体分散体及其制剂 |
| CA3052229A1 (en) * | 2017-02-14 | 2018-08-23 | Dsm Ip Assets B.V. | Storage-stable formulations |
| NZ755865A (en) * | 2017-02-14 | 2022-01-28 | Dsm Ip Assets Bv | Water dispersible formulations |
| CN110013467B (zh) | 2018-01-10 | 2021-09-17 | 上海汉都医药科技有限公司 | 一种固体微粒及其制备方法和含其的药物组合物 |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| JP2022069437A (ja) * | 2020-10-23 | 2022-05-11 | 富士製薬工業株式会社 | 医薬製剤およびその製造方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA72698B (en) | 1972-02-03 | 1973-09-26 | Liebenberg R W | Method of preparing medicinal compositions |
| US4013785A (en) * | 1975-03-21 | 1977-03-22 | Bristol-Myers Company | Apap tablet containing fumed silica and process for manufacturing same |
| DE2845326C2 (de) * | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung |
| GB8403359D0 (en) | 1984-02-08 | 1984-03-14 | Erba Farmitalia | Pharmaceutical compositions |
| IT1216570B (it) * | 1988-04-08 | 1990-03-08 | Vectorpharma Int | Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione. |
| DE3916112A1 (de) * | 1989-05-16 | 1990-11-22 | Schering Ag | Dihydrospirorenon als antiandrogen |
| ES2062634T3 (es) | 1990-08-30 | 1994-12-16 | Senju Pharma Co | Composicion con liberacion controlada del farmaco. |
| ATE118178T1 (de) * | 1990-11-29 | 1995-02-15 | Faulding F H & Co Ltd | Verfahren zur herstellung von flüssigkeiten enthaltenden pulvern. |
| DE4326240A1 (de) * | 1993-08-02 | 1995-02-09 | Schering Ag | 15,15-Dialkyl-substituierte Derivate des Estradiols |
| US5585115A (en) * | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| US5789442A (en) * | 1996-01-18 | 1998-08-04 | Schering Aktiengesellschaft | Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents |
| US5800834A (en) | 1996-06-10 | 1998-09-01 | Spireas; Spiridon | Liquisolid systems and methods of preparing same |
| US6027747A (en) | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
| KR20000000016A (ko) | 1999-02-10 | 2000-01-15 | 김일 | 자동차용번호판부착볼트구조 |
| ES2319750T3 (es) * | 1999-08-31 | 2009-05-12 | Bayer Schering Pharma Aktiengesellschaft | Composicion farmaceutica que comprende etinilestradiol y drospirenona para usar como anticonceptivo. |
| US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| EE05533B1 (et) | 2000-01-18 | 2012-04-16 | Schering Aktiengesellschaft | Farmatseutiline kompositsioon ja preparaat, mis sisaldab mikroniseeritud drospirenooni ja strogeeni ning nende kasutamine |
| EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| BR0210519A (pt) * | 2001-06-22 | 2004-06-22 | Pfizer Prod Inc | Composições farmacêuticas de adsorvatos de fármaco amorfo |
| ITMC20010031U1 (it) | 2001-07-05 | 2003-01-07 | Best Raffaello Srl | Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo |
| SE0103838D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Pharmaceutical formulation & product |
| CN101785775B (zh) | 2002-09-05 | 2015-03-25 | 潘塔希生物科学股份有限公司 | 15-或16-位取代的睾酮类似物的药物学应用 |
| AU2003278434A1 (en) | 2002-11-05 | 2004-06-07 | Schering Aktiengesellschaft | Cardiovascular protection using anti-aldosteronic progestins |
| DE20217332U1 (de) | 2002-11-11 | 2003-02-27 | Brand Factory Swiss Gmbh, Rotkreuz | Socke |
| CA2516096A1 (en) * | 2003-02-19 | 2004-09-02 | Lifecycle Pharma A/S | Use of a silica or silica derivative as a sorption material |
| FR2851918B1 (fr) | 2003-03-06 | 2006-06-16 | Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication | |
| EP1748756B1 (en) | 2004-03-10 | 2009-04-29 | Bayer Schering Pharma Aktiengesellschaft | Compositions comprising drospirenone molecularly dispersed |
-
2005
- 2005-03-09 MY MYPI20050963A patent/MY142989A/en unknown
- 2005-03-10 EA EA200601588A patent/EA012746B1/ru not_active IP Right Cessation
- 2005-03-10 HR HR20090614T patent/HRP20090614T1/hr unknown
- 2005-03-10 SI SI200530840T patent/SI1765290T1/sl unknown
- 2005-03-10 PL PL05718248T patent/PL1765290T3/pl unknown
- 2005-03-10 PE PE2005000277A patent/PE20060016A1/es not_active Application Discontinuation
- 2005-03-10 GT GT200500045A patent/GT200500045A/es unknown
- 2005-03-10 UY UY28803A patent/UY28803A1/es not_active Application Discontinuation
- 2005-03-10 AU AU2005221403A patent/AU2005221403B8/en not_active Ceased
- 2005-03-10 AR ARP050100924A patent/AR048500A1/es not_active Application Discontinuation
- 2005-03-10 CN CN2005800150633A patent/CN1984644B/zh not_active Expired - Fee Related
- 2005-03-10 EP EP05718248A patent/EP1765290B1/en not_active Expired - Lifetime
- 2005-03-10 CA CA2558582A patent/CA2558582C/en not_active Expired - Fee Related
- 2005-03-10 ES ES09161378T patent/ES2390406T3/es not_active Expired - Lifetime
- 2005-03-10 EP EP09161378A patent/EP2087883B1/en not_active Expired - Lifetime
- 2005-03-10 NZ NZ549793A patent/NZ549793A/en unknown
- 2005-03-10 DE DE602005016551T patent/DE602005016551D1/de not_active Expired - Lifetime
- 2005-03-10 TW TW094107345A patent/TWI345986B/zh not_active IP Right Cessation
- 2005-03-10 JP JP2007502437A patent/JP5006185B2/ja not_active Expired - Fee Related
- 2005-03-10 PA PA20058626101A patent/PA8626101A1/es unknown
- 2005-03-10 ES ES05718248T patent/ES2332229T3/es not_active Expired - Lifetime
- 2005-03-10 PT PT05718248T patent/PT1765290E/pt unknown
- 2005-03-10 RS RSP-2009/0508A patent/RS51076B/sr unknown
- 2005-03-10 AT AT05718248T patent/ATE442131T1/de active
- 2005-03-10 SV SV2005002044A patent/SV2005002044A/es unknown
- 2005-03-10 BR BRPI0507342-1A patent/BRPI0507342A/pt not_active IP Right Cessation
- 2005-03-10 WO PCT/IB2005/000748 patent/WO2005087199A2/en not_active Ceased
- 2005-03-10 DK DK05718248T patent/DK1765290T3/da active
- 2005-03-10 US US11/076,022 patent/US8715735B2/en not_active Expired - Fee Related
-
2006
- 2006-09-05 IL IL177894A patent/IL177894A0/en unknown
- 2006-09-14 CR CR8630A patent/CR8630A/es unknown
- 2006-10-02 EC EC2006006902A patent/ECSP066902A/es unknown
- 2006-10-02 NO NO20064473A patent/NO20064473L/no not_active Application Discontinuation
- 2006-10-09 KR KR1020067020937A patent/KR101210695B1/ko not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007528389A5 (enExample) | ||
| HRP20090614T1 (hr) | Stabilizirane superzasićene krute otopine steroidnih lijekova | |
| EP1980242B1 (en) | Liquid compositions as a micro-emulsion pre-concentrate comprising drospirenone moleculary dispersed | |
| US20050220825A1 (en) | Molecular dispersions of drospirenone | |
| CA2194979C (en) | Solid drug forms containing clathrates of steroid sex hormones | |
| WO1999015156B1 (en) | Inhibition of crystallization in transdermal devices | |
| WO2014178065A1 (en) | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | |
| JP2011502172A5 (enExample) | ||
| EP1904028A1 (en) | Estrogen compositions for vaginal administration | |
| JP2010502624A (ja) | 低ｐＨ親和性を有するコルチコステロイド化合物及びビタミンＤ含有化合物を含む安定な薬理活性組成物 | |
| KR927003617A (ko) | 스테로이드성 유기물질의 결정화방법 및 이 방법으로 얻어지는 화합물 | |
| JP2008534533A5 (enExample) | ||
| JPH09506900A (ja) | 薬物の乾燥混和物圧縮法 | |
| MXPA06010256A (en) | Stabilised supersaturated solids of lipophilic drugs | |
| HK1232125A1 (zh) | 用於抗孕激素的阴道递送的制剂和方法 | |
| HK1103660B (en) | Stabilised supersaturated solids of lipophilic drugs |